Cite
Sclerostin antibody treatment improves fracture outcomes in a Type I diabetic mouse model.
MLA
Yee, Cristal S., et al. “Sclerostin Antibody Treatment Improves Fracture Outcomes in a Type I Diabetic Mouse Model.” BONE, vol. 82, Jan. 2016, pp. 122–34. EBSCOhost, https://doi.org/10.1016/j.bone.2015.04.048.
APA
Yee, C. S., Xie, L., Hatsell, S., Hum, N., Murugesh, D., Economides, A. N., Loots, G. G., & Collette, N. M. (2016). Sclerostin antibody treatment improves fracture outcomes in a Type I diabetic mouse model. BONE, 82, 122–134. https://doi.org/10.1016/j.bone.2015.04.048
Chicago
Yee, Cristal S., LiQin Xie, Sarah Hatsell, Nicholas Hum, Deepa Murugesh, Aris N. Economides, Gabriela G. Loots, and Nicole M. Collette. 2016. “Sclerostin Antibody Treatment Improves Fracture Outcomes in a Type I Diabetic Mouse Model.” BONE 82 (January): 122–34. doi:10.1016/j.bone.2015.04.048.